VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 67.9% in April

VanEck Biotech ETF (NASDAQ:BBH) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,500 shares, a decline of 67.9% from the March 31st total of 7,800 shares. Based on an average daily trading volume, of 7,200 shares, the short-interest ratio is currently 0.3 days.

VanEck Biotech ETF Stock Performance

NASDAQ BBH traded up $0.82 during trading hours on Friday, hitting $155.59. 6,398 shares of the company’s stock were exchanged, compared to its average volume of 10,021. The business’s 50 day moving average is $162.21 and its 200-day moving average is $159.75. VanEck Biotech ETF has a 12-month low of $142.51 and a 12-month high of $171.04.

Institutional Trading of VanEck Biotech ETF

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Anchor Investment Management LLC acquired a new stake in VanEck Biotech ETF during the 4th quarter worth approximately $26,000. Tidemark LLC acquired a new stake in shares of VanEck Biotech ETF in the fourth quarter worth $34,000. Principal Securities Inc. purchased a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $66,000. Assetmark Inc. purchased a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at $135,000. Finally, Howard Wealth Management LLC acquired a new position in shares of VanEck Biotech ETF during the 4th quarter valued at $201,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.